Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFα

Clinical Rheumatology

Volumn 26, Issue 11, 2007, Pages 1867-1870

  Hanta, Ismail ^a   Ozbek, Suleyman ^a   Kuleci, Sedat ^a   Sert, Murat ^a   Kocabas, Ali ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Anti TNF therapy; Isoniazid intervention; Latent tuberculosis

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETANERCEPT; INFLIXIMAB; ISONIAZID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COLORIMETRY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TUBERCULOSIS;

ADULT; ALANINE TRANSAMINASE; ANTITUBERCULAR AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; ASPARTATE AMINOTRANSFERASES; COLORIMETRY; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34948909204     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0591-4     Document Type: Article

References (19)

1. Keane J (2005) TNF-blocking agents and tuberculosis: New drugs illuminate and old topic. Rheumatology 44:714-720
2. Ellerin T, Hurtado R, Lockman S et al (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48(11):3013-3022
3. Kroesen S, Widmer AF, Tyndall A et al (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42(5):617-621
4. Khanna D, McMahon M, Furst DE (2004) Safety of tumour necrosis factor-α antagonists. Drug Saf 27(5):307-324
5. Long R, Gardam M (2003) Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. CMAJ 168(9):1153-1156
6. Mutlu G, Mutlu E, Bellmeyer A et al (2006) Pulmonary adverse events of anti tumour necrosis factor-α antibody therapy. Am J Med 119:639-646
7. American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 61:S221-S247
8. British Thoracic Society Standards of Care Commitee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 60:800-805
9. Vanhoof J, Landewe S, Wijngaerden E et al (2003) High Incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 62:1241-1242
10. Sichletidis L, Settas L, Spyratos D et al (2006) Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10(10):1127-1132
11. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
12. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-367
13. Kunst H (2006) Diagnosis of latent tuberculosis infection: The potential role of new technologies. Respir Med 100:2098-2106
14. Wolfe F, Michaud K, Anderson J et al (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50(2):372-379
15. American Thoracic Society, CDC, and Infectious Diseases Society of America (2003) MMWR vol 52. No. RR-11
16. Fountain F, Tolley E, Chrisman C et al (2005) Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection. Chest 128:116-123
17. American Thoracic Society Documents (2006) Ann official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935-952
18. Gaitonde S, Pathan E, Sule A et al (2002) Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 61:251-253
19. Vikrant S, Agarwal SK, Gupta S (2005) Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis 7(3-4):99-108